The Native Antigen Company, part of LGC Clinical Diagnostics and one of the world’s leading suppliers of reagents that enables research into diagnostics and vaccines for emerging and endemic infectious diseases, today announced the launch of its SARS-CoV-2 Neutralisation Assay Development Kit. The kit can be used to identify and qualitatively assess the ability of antibodies to neutralize SARS-CoV-2-receptor binding, to support research into variants and their effects on natural and vaccine-induced patient immunity.
The easy-to-use kit contains all the key reagents required to measure SARS-CoV-2-antibody binding, including the Spike receptor-binding domain (RBD) of the prototypic Wuhan-Hu-1 strain, labeled ACE2, and positive and negative monoclonal antibody controls. These reagents enable the assessment of neutralizing activity of patient and therapeutic antibodies and can be used alongside The Native Antigen Company’s growing range of SARS-CoV-2 variant Spike proteins to assess
Two new units have been created at Didcot Quarter. Work also began on the National Space Propulsion Test Facility at Westcott Venture Park in Buckinghamshire. The centre will enable UK companies and academics to test space propulsion engines which will aid the growth of Oxfordshire s space industry. The Native Antigen Company has agreed to lease a research and development and manufacturing building at the Oxford Technology Park set to be completed this summer. The electric commercial vehicle manufacturer Arrival Automotive have taken the final unit at Link 9 Bicester where they already occupy two units. And planning permission for a new space at Didcot’s Harwell Campus was granted in February and should be completed early next year.
Saliva-based testing as a method for monitoring population immunity to SARS-CoV-2 infection
Researchers in the United States have shown that saliva-based sampling could serve as an accurate and non-invasive alternative to blood sampling for monitoring people’s antibody responses following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or vaccination against the virus.
The SARS-CoV-2 virus is the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic that continues to pose a threat to global public health and has now caused more than 2.66 million deaths worldwide.
Christopher Heaney from Johns Hopkins University in Baltimore and colleagues assessed the durability of immunoglobulin G (IgG) antibodies against three SARS-CoV-2 antigens in saliva samples collected from more than 200 people up to 8 months after they tested positive for the virus.
Lateral Flow Assays Market 2021 Global Analysis & Forecast to 2027 Market Research Report sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.